BRIEF-Biocytogen Pharmaceuticals Beijing Sees FY Revenue To Be Between RMB969.3 Mln And RMB989.3 Mln

Reuters

2025/01/27

Jan 27 (Reuters) - Biocytogen Pharmaceuticals Beijing Co Ltd 2315.HK:

FY REVENUE EXPECTED TO BE ABOUT RMB969.3 MILLION TO RMB989.3 MILLION
EXPECTED RESULT DUE TO RECOGNITION OF ANTIBODY DISCOVERY BUSINESS BY OVERSEAS CUSTOMERS, OTHERS
NET PROFIT FOR YEAR EXPECTED TO BE APPROXIMATELY RMB20 MILLION TO RMB40 MILLION

Further company coverage: 2315.HK

((Reuters.Briefs@thomsonreuters.com;))

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2506130327"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2506130327\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2506130327?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-27 18:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2506130327","market":"us","top_or_hot":-1,"title":"BRIEF-Biocytogen Pharmaceuticals Beijing Sees FY Revenue To Be Between RMB969.3 Mln And RMB989.3 Mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Biocytogen Pharmaceuticals Beijing Sees FY Revenue To Be Between RMB969.3 Mln And RMB989.3 Mln</title></head><body><p><span>Jan 27 (Reuters)</span><span> - </span>Biocytogen Pharmaceuticals Beijing Co Ltd <span>2315.HK</span>:</p><ul><li><p>FY REVENUE EXPECTED TO BE ABOUT RMB969.3 MILLION TO RMB989.3 MILLION</p></li><li><p>EXPECTED RESULT DUE TO RECOGNITION OF ANTIBODY DISCOVERY BUSINESS BY OVERSEAS CUSTOMERS, OTHERS</p></li><li><p>NET PROFIT FOR YEAR EXPECTED TO BE APPROXIMATELY RMB20 MILLION TO RMB40 MILLION</p></li></ul><p>Further company coverage: <span>2315.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Biocytogen Pharmaceuticals Beijing Sees FY Revenue To Be Between RMB969.3 Mln And RMB989.3 Mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Biocytogen Pharmaceuticals Beijing Sees FY Revenue To Be Between RMB969.3 Mln And RMB989.3 Mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-27 18:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Biocytogen Pharmaceuticals Beijing Sees FY Revenue To Be Between RMB969.3 Mln And RMB989.3 Mln</title></head><body><p><span>Jan 27 (Reuters)</span><span> - </span>Biocytogen Pharmaceuticals Beijing Co Ltd <span>2315.HK</span>:</p><ul><li><p>FY REVENUE EXPECTED TO BE ABOUT RMB969.3 MILLION TO RMB989.3 MILLION</p></li><li><p>EXPECTED RESULT DUE TO RECOGNITION OF ANTIBODY DISCOVERY BUSINESS BY OVERSEAS CUSTOMERS, OTHERS</p></li><li><p>NET PROFIT FOR YEAR EXPECTED TO BE APPROXIMATELY RMB20 MILLION TO RMB40 MILLION</p></li></ul><p>Further company coverage: <span>2315.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3OL0FJ:1","article_id":"2506130327","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2506130327","pubTimestamp":1737974384,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Biocytogen Pharmaceuticals Beijing Sees FY Revenue To Be Between RMB969.3 Mln And RMB989.3 MlnJan 27  - Biocytogen Pharmaceuticals Beijing Co Ltd 2315.HK:FY REVENUE EXPECTED TO BE ABOUT RMB969.3 MILLION TO RMB989.3 MILLIONEXPECTED RESULT DUE TO RECOGNITION OF ANTIBODY DISCOVERY BUSINESS BY OVERSEAS CUSTOMERS, OTHERSNET PROFIT FOR YEAR EXPECTED TO BE APPROXIMATELY RMB20 MILLION TO RMB40 MILLIONFurther company coverage: 2315.HK ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"简介-北京百奥赛图药业预计财年收入将在人民币9.693亿元至人民币9.893亿元之间","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":0.9},"content_text":"BRIEF-Biocytogen Pharmaceuticals Beijing Sees FY Revenue To Be Between RMB969.3 Mln And RMB989.3 MlnJan 27 (Reuters) - Biocytogen Pharmaceuticals Beijing Co Ltd 2315.HK:FY REVENUE EXPECTED TO BE ABOUT RMB969.3 MILLION TO RMB989.3 MILLIONEXPECTED RESULT DUE TO RECOGNITION OF ANTIBODY DISCOVERY BUSINESS BY OVERSEAS CUSTOMERS, OTHERSNET PROFIT FOR YEAR EXPECTED TO BE APPROXIMATELY RMB20 MILLION TO RMB40 MILLIONFurther company coverage: 2315.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}